TREATMENT PATTERNS IN MEDICAID BENEFICIARIES WITH SCHIZOPHRENIA REACHING STABILIZED MAINTENANCE WITH ONCE-MONTHLY PALIPERIDONE PALMITATE THERAPY

被引：1
|
作者：
Pilon, D. [1 ]
Muser, E. [2 ]
Emond, B. [1 ]
Xiao, Y. [1 ]
Amos, T. [2 ]
Lefebvre, P. [1 ]
Benson, C. [2 ]
机构：
[1] Grp Anal Ltee, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1868
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMH82
引用
收藏
页码：A196 / A196
页数：1
相关论文
共 50 条
  • [41] Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
    Pilon, Dominic
    Muser, Erik
    Lefebvre, Patrick
    Kamstra, Rhiannon
    Emond, Bruno
    Joshi, Kruti
    BMC PSYCHIATRY, 2017, 17
  • [42] Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    PSYCHOGERIATRICS, 2022, 22 (01) : 159 - 160
  • [43] The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia
    El Khoury, Antoine C.
    Pilon, Dominic
    Morrison, Laura
    Shak, Nina
    Vermette-Laforme, Maude
    Amos, Tony B.
    Kim, Edward
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (03) : 395 - 405
  • [44] A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly
    Geerts, Hugo
    Spiros, Athan
    Roberts, Patrick
    Alphs, Larry
    SCHIZOPHRENIA RESEARCH, 2018, 197 : 261 - 268
  • [45] Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions
    Georgios Schoretsanitis
    Ekkehard Haen
    Daria Piacentino
    Andreas Conca
    Katharina Endres
    Fabio Carpi
    Christoph Hiemke
    Gerhard Gründer
    Michael Paulzen
    Clinical Pharmacokinetics, 2021, 60 : 1583 - 1589
  • [46] Once-monthly paliperidone palmitate versus daily oral antipsychotics delays adverse real-world consequences of schizophrenia
    Starr, H.
    Mao, L.
    Rodriguez, S.
    Alphs, L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S550 - S551
  • [47] EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA WITH LOW, MODERATE, AND HIGH RECENT DISEASE ACTIVITY AT BASELINE
    Lynum, Karimah
    Turkoz, Ibrahim
    Kim, Edward
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S317 - S318
  • [48] Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions
    Schoretsanitis, Georgios
    Haen, Ekkehard
    Piacentino, Daria
    Conca, Andreas
    Endres, Katharina
    Carpi, Fabio
    Hiemke, Christoph
    Gruender, Gerhard
    Paulzen, Michael
    CLINICAL PHARMACOKINETICS, 2021, 60 (12) : 1583 - 1589
  • [49] Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
    Si, Tianmei
    Zhuo, Jianmin
    Feng, Yu
    Lu, Huafei
    Hong, Di
    Zhang, Lili
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 1685 - 1694
  • [50] Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
    Li, Gang
    Keenan, Alexander
    Daskiran, Mehmet
    Mathews, Maju
    Nuamah, Isaac
    Orman, Camille
    Joshi, Kruti
    Singh, Arun
    Godet, Annabelle
    Pungor, Katalin
    Gopal, Srihari
    PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 2239 - 2248
12345